Cefiderocol for treatment of complicated urinary tract infections - Author's reply

Affiliations

Comment

Angela Huttner. Lancet Infect Dis. 2019 Jan.

. 2019 Jan;19(1):24-25.

doi: 10.1016/S1473-3099(18)30728-X.

¹ Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland. Electronic address: angela.huttner@hcuge.ch.

No abstract available

Comment on

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD. Portsmouth S, et al. Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25. Lancet Infect Dis. 2018. PMID: 30509675 Clinical Trial.
Cefiderocol for treatment of complicated urinary tract infections.
Wagenlehner FME, Naber KG. Wagenlehner FME, et al. Lancet Infect Dis. 2019 Jan;19(1):22-23. doi: 10.1016/S1473-3099(18)30722-9. Lancet Infect Dis. 2019. PMID: 30587289 No abstract available.
Cefiderocol for treatment of complicated urinary tract infections.
Portsmouth S, Echols R, Den Nagata T. Portsmouth S, et al. Lancet Infect Dis. 2019 Jan;19(1):23-24. doi: 10.1016/S1473-3099(18)30721-7. Lancet Infect Dis. 2019. PMID: 30587290 No abstract available.